Stock Research for AERI

AERI

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

AERI Stock Chart & Research Data

The AERI chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AERI chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


AERI Due diligence Resources & Stock Charts

The AERI stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View AERI Detailed Price Forecast - CNN Money CNN View AERI Detailed Summary - Google Finance
Yahoo View AERI Detailed Summary - Yahoo! Finance Zacks View AERI Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View AERI Trends & Analysis - Trade-Ideas Barrons View AERI Major Holders - Barrons
NASDAQ View AERI Call Transcripts - NASDAQ Seeking View AERI Breaking News & Analysis - Seeking Alpha
Spotlight View AERI Annual Report - CompanySpotlight.com OTC Report View AERI OTC Short Report - OTCShortReport.com
TradeKing View AERI Fundamentals - TradeKing Charts View AERI SEC Filings - Bar Chart
WSJ View Historical Prices for AERI - The WSJ Morningstar View Performance/Total Return for AERI - Morningstar
MarketWatch View the Analyst Estimates for AERI - MarketWatch CNBC View the Earnings History for AERI - CNBC
StockMarketWatch View the AERI Earnings - StockMarketWatch MacroAxis View AERI Buy or Sell Recommendations - MacroAxis
Bullish View the AERI Bullish Patterns - American Bulls Short Pains View AERI Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View AERI Stock Mentions - StockTwits PennyStocks View AERI Stock Mentions - PennyStockTweets
Twitter View AERI Stock Mentions - Twitter Invest Hub View AERI Investment Forum News - Investor Hub
Yahoo View AERI Stock Mentions - Yahoo! Message Board Seeking Alpha View AERI Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for AERI - SECform4.com Insider Cow View Insider Transactions for AERI - Insider Cow
CNBC View AERI Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for AERI - OTC Markets
Yahoo View Insider Transactions for AERI - Yahoo! Finance NASDAQ View Institutional Holdings for AERI - NASDAQ


Stock Charts

FinViz View AERI Stock Insight & Charts - FinViz.com StockCharts View AERI Investment Charts - StockCharts.com
BarChart View AERI Stock Overview & Charts - BarChart Trading View View AERI User Generated Charts - Trading View


Latest Financial News for AERI

Are Aerie Pharmaceuticals Inc’s (NASDAQ:AERI) Interest Costs Too High?
Posted on Thursday May 17, 2018

Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Aerie Pharmaceuticals Inc (NASDAQ:AERI), with a market capitalization of US$2.02B, rarely draw their attention from the investingRead More...


Wired News – Eli Lilly’s Galcanezumab Met Primary Endpoint in Phase-3 Study for Prevention of Episodic Cluster Headache
Posted on Thursday May 17, 2018

LONDON, UK / ACCESSWIRE / May 17, 2018 / If you want access to our free research report on Eli Lilly and Co. (NYSE: LLY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=LLY as the Company's latest news hit the wire. On May 15, 2018, the Company announced that a Phase-3 study evaluating galcanezumab in patients with episodic cluster headache met its primary endpoint, demonstrating statistically significant differences in the reduction of weekly cluster headache attacks compared to placebo across weeks one to three of the two-month, double-blind treatment period. There were also a statistically significantly greater percentage of patients treated with galcanezumab who achieved at least a 50% reduction in weekly cluster headache attacks compared to placebo at Week 3, the gated secondary endpoint.


Aerie submits second drug for FDA approval
Posted on Tuesday May 15, 2018

Aerie Pharmaceuticals has submitted its second glaucoma drug, Roclatan, to the U.S. Food and Drug Administration for potential approval.


Benzinga Pro's 5 Stocks To Watch Today
Posted on Tuesday May 15, 2018

Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! MEDIGUS Ltd/S ADR (NASDAQ: MDGS ) stock gained more ...


Enter a stock symbol to view the stock details.